ReviewAging and disease2025
Monocytes/Macrophages in Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease.
Review in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related inflammatory diseases that predominantly affect individuals over 50 years of age. The pathogenesis of two diseases is unclear. Accumulating evidence indicates that aberrant innate and adaptive immune responses underlie the pathogenesis of GCA and PMR. Monocytes/macrophages play an important role in the inflammatory processes through producing proinflammatory cytokines and chemokines, modulating molecular expression, colony-stimulating factors, proteolytic enzymes, and growth factors, and activating the JAK/STAT pathway. Clarifying the functions of monocytes/macrophages may help find targets for these diseases. Current research is investigating potential treatments such as proinflammatory cytokine blockers, anti-CXCR3 agents, competitive antagonists of GM-CSF activity, and JAK inhibitors in patients with GCA or PMR. In this study, we examine the role of monocytes and macrophages in the pathogenesis of GCA and PMR, identify potential drug targets, novel therapeutic strategies and future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.